Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department for Business, Energy and Industrial Strategy:
To ask the Secretary of State for Business, Energy and Industrial Strategy, if he will list those companies manufacturing vaccines or developing vaccines in the UK which use (a) messenger RNA and (b) inactivated virus.
Answered by George Freeman
The Government’s approach to seeking a vaccine for COVID-19 has, from the outset, been to secure access to a portfolio of candidate vaccines from a range of developers. This has resulted in four regulated COVID-19 vaccines within the portfolio to date providing both diversity of supply and diversity of vaccine type.
The Government has secured early access to 332 million COVID-19 vaccines doses through supply agreements with five separate vaccine developers. This includes agreements with:
Of these COVID-19 vaccines, the AstraZeneca vaccine is manufactured in the UK and Novavax has a UK supply chain subject to regulatory approval. Vaccine manufacture is a global business, and the response to COVID-19 a global effort, and we are proud of AstraZeneca’s contribution to that from the UK.
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department for Business, Energy and Industrial Strategy:
To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps he is taking to ensure diversity of (a) suppliers and (b) technology within vaccine provision in the context of the notice of termination of the covid-19 vaccine supply agreement with Valneva.
Answered by George Freeman
The Government’s approach to seeking a vaccine for COVID-19 has, from the outset, been to secure access to a portfolio of candidate vaccines from a range of developers. This has resulted in four regulated COVID-19 vaccines within the portfolio to date providing both diversity of supply and diversity of vaccine type.
The Government has secured early access to 332 million COVID-19 vaccines doses through supply agreements with five separate vaccine developers. This includes agreements with:
Of these COVID-19 vaccines, the AstraZeneca vaccine is manufactured in the UK and Novavax has a UK supply chain subject to regulatory approval. Vaccine manufacture is a global business, and the response to COVID-19 a global effort, and we are proud of AstraZeneca’s contribution to that from the UK.
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department for Business, Energy and Industrial Strategy:
To ask the Secretary of State for Business, Energy and Industrial Strategy, what contingency measures the Government has put in place to ensure adequacy of covid-19 vaccine supply in response to the Government's notice of termination of the covid-19 vaccine supply agreement with Valneva.
Answered by George Freeman
Our vaccination programme is continuing to make phenomenal progress, with four out of every five adults now fully vaccinated against COVID-19.
I cannot comment on commercial decisions, the termination of our supply agreement with Valneva will have no impact on our vaccine supplies for autumn.
The UK has contracted for a portfolio of vaccines from a number of developers, and we have sufficient contracted supply for the expected booster campaign as well as to complete the first round of vaccinations.
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department for Business, Energy and Industrial Strategy:
To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment he has made of the impact of the UK Government's notice of termination of the covid-19 vaccine supply agreement with Valneva on his Department’s ability to meet vaccine supply requirements.
Answered by George Freeman
Our vaccination programme is continuing to make phenomenal progress, with four out of every five adults now fully vaccinated against COVID-19.
I cannot comment on commercial decisions, the termination of our supply agreement with Valneva will have no impact on our vaccine supplies for autumn.
The UK has contracted for a portfolio of vaccines from a number of developers, and we have sufficient contracted supply for the expected booster campaign as well as to complete the first round of vaccinations.
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department for Business, Energy and Industrial Strategy:
To ask the Secretary of State for Business, Energy and Industrial Strategy, what discussions (a) he and (b) Ministers in his Department have had with the Scottish Government since the UK Government's notice of termination of the covid-19 vaccine supply agreement with Valneva was issued, on that matter.
Answered by George Freeman
Ministers regularly discuss COVID-19 vaccine matters with the Scottish Government and other devolved administrations.
My Rt. Hon. Friend the Secretary of State for Health has discussed the termination of our supply agreement with Valneva with his counterpart in the Scottish Government and the UK Government will maintain dialogue with the Scottish Government on this matter.
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department for Business, Energy and Industrial Strategy:
To ask the Secretary of State for Business, Energy and Industrial Strategy, whether he has received a request from the Scottish Government to discuss the impact of the UK Government's notice of termination of the covid-19 vaccine supply agreement with Valneva.
Answered by George Freeman
Ministers regularly discuss COVID-19 vaccine matters with the Scottish Government and other devolved administrations.
My Rt. Hon. Friend the Secretary of State for Health has discussed the termination of our supply agreement with Valneva with his counterpart in the Scottish Government and the UK Government will maintain dialogue with the Scottish Government on this matter.
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department for Business, Energy and Industrial Strategy:
To ask the Secretary of State for Business, Energy and Industrial Strategy, whether he has received a request from the Scottish Government to discuss the impact on Scotland of the UK Government's notice of termination of the COVID-19 Vaccine Supply Agreement with Valneva.
Answered by George Freeman
Ministers regularly discuss COVID-19 vaccine matters with the Scottish Government and other devolved administrations.
My Rt. Hon. Friend the Secretary of State for Health has discussed the termination of our supply agreement with Valneva with his counterpart in the Scottish Government and the UK Government will maintain dialogue with the Scottish Government on this matter.
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department for Business, Energy and Industrial Strategy:
To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment he has made of the impact of the UK Government's notice of termination of the covid-19 vaccine supply agreement with Valneva on (a) vaccine provision and (b) science, research and innovation in the UK.
Answered by George Freeman
The UK has contracted for a portfolio of vaccines from a number of developers, and we have sufficient contracted supply for the expected booster campaign as well as to complete the first round of vaccinations.
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department for Business, Energy and Industrial Strategy:
To ask the Secretary of State for Business, Energy and Industrial Strategy, what funding he has allocated to support charity-funded medical research.
Answered by Amanda Solloway
I refer the Hon. Member to the answer I gave the Hon. Member for Central Ayrshire on 1st December 2020 to Question 121276.